When Viela Bio spun out of MedImmune in March, it started with six assets — three in clinical trials and three in preclinical development — putting it ahead of most startups and many spin-offs. “Other spin-offs often are developing assets that have been shelved for various reasons or that have been deprioritized,” Bing Yao, Ph.D., CEO, notes. “But for Viela Bio, this is a continuation of the programs, not a handoff.”
{iframe}https://www.lifescienceleader.com/doc/why-a-spin-off-is-a-win-win-for-big-pharma-and-startups-0001{/iframe}